Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in japan

J Vasc Surg. 2000 Aug;32(2):263-7. doi: 10.1067/mva.2000.105670.

Abstract

Purpose: Plasma platelet-activating factor acetylhydrolase (PAF-AH) is known to catalyze platelet-activating factor, thereby inactivating its inflammatory function. Deficiency of this enzyme is caused by a missense (G(994)-->T) in exon 9 of the plasma PAF-AH gene. In this study, we investigated a possible association of this mutation with the risk of atherosclerotic occlusive disease (AO) in Japanese patients.

Methods: We studied 104 patients with AO. The control group consisted of 114 subjects matched for age and sex. Plasma PAF-AH activity was measured in the patients with AO.

Results: The prevalence of the mutant genotype (GT + TT ) was significantly more frequent in patients with AO than in control subjects (36.5% vs 23.7%; P <.05). Among the patients with AO, those with the mutant allele had significantly more risk factors of prior stroke or ischemic heart disease than patients with normal genotypes. Plasma PAF-AH activity was higher in patients with AO than in control subjects in normal genotype subgroups.

Conclusions: The missense (G(994)-->T) in exon 9 of the plasma PAF-AH gene is associated with AO in Japanese people.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Alkyl-2-acetylglycerophosphocholine Esterase
  • Aged
  • Arteriosclerosis / etiology*
  • Arteriosclerosis / genetics*
  • Female
  • Genotype
  • Humans
  • Japan
  • Male
  • Mutation
  • Phospholipases A / deficiency*
  • Phospholipases A / genetics*
  • Platelet Activating Factor / deficiency*
  • Platelet Activating Factor / genetics*

Substances

  • Platelet Activating Factor
  • Phospholipases A
  • 1-Alkyl-2-acetylglycerophosphocholine Esterase